Composition including gelsolin as effective ingredient for inducing differentiation into dendritic cell and method of inducing differentiation into dendritic cell

Abstract

Disclosed are a composition including gelsolin as an effective ingredient for inducing differentiation into a dendritic cell, a method of inducing differentiation by using the composition, and a vaccine composition for treating cancer or an immune-mediated disease. In addition, a composition including gelsolin as an effective ingredient for inducing differentiation into a dendritic cell and a method of inducing differentiation into a dendritic cell by treating an immature dendritic cell with gelsolin are also disclosed. Further, a dendritic cell differentiated by using the method of inducing differentiation into the dendritic cell and a vaccine composition including the dendritic cell as an effective ingredient for treating cancer or an immune-mediated disease are disclosed.

What is claimed is: 
     
         1 . A method of inducing differentiation into a dendritic cell, comprising:
 providing a composition comprising gelsolin as an active ingredient.   
     
     
         2 . The method of  claim 1 , wherein the dendritic cell comprises at least one positive immunological characteristic on a surface antigen selected from the group consisting of CD40, CD80, CD86, and MHC class II molecules. 
     
     
         3 . A method of inducing differentiation into a dendritic cell, the method comprising:
 treating an immature dendritic cell with gelsolin.   
     
     
         4 . The method of  claim 3 , wherein the immature dendritic cell is obtained by treating a bone marrow-derived hematopoietic stem cell with interleukin-4 (IL-4) and a granulocyte-macrophage colony-stimulating factor (GM-CSF). 
     
     
         5 . The method of  claim 3 , wherein the gelsolin is treated in a concentration of 0.1 to 5 μg/ml for 12 to 48 hours. 
     
     
         6 . A dendritic cell differentiated by the method of  claim 3 . 
     
     
         7 . The dendritic cell of  claim 6 , wherein the dendritic cell is characterized by an increased amount of cytokine, such as IL-12p70 and IL-23. 
     
     
         8 . The dendritic cell of  claim 6 , wherein the dendritic cell increases proliferation of a T lymphocyte and secretion of cytokine, such as IFN-γ and IL-4. 
     
     
         9 . A vaccine composition including the dendritic cell of  claim 6  as an effective ingredient for treating cancer or an immune-mediated disease. 
     
     
         10 . The vaccine composition of  claim 9 , wherein a type of the cancer is breast cancer. 
     
     
         11 . The vaccine composition of  claim 9 , wherein the immune-mediated disease is asthma or atopy.